Hemorrhage, Surgical
0
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
CytoSorbentsPRINCETON, NJ
3 programsCytoSorbN/A1 trial
DrugSorb-ATR systemN/A1 trial
Sham comparatorN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
CytoSorbentsSham comparator
CytoSorbentsCytoSorb
CytoSorbentsDrugSorb-ATR system
Clinical Trials (3)
Total enrollment: 1,149 patients across 3 trials
Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)
Start: Dec 2021Est. completion: Jan 20249 patients
N/ATerminated
Safe and Timely Antithrombotic Removal (STAR) Registry
Start: Sep 2021Est. completion: Sep 20301,000 patients
N/AActive Not Recruiting
Safe and Timely Antithrombotic Removal - Ticagrelor (STAR-T)
Start: Aug 2021Est. completion: Aug 2023140 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.